2 world-class ASX 50 shares to buy for your portfolio

Analysts are saying good things about these

| More on:
world's biggest companies represented by one person holding cityscape and another holding earth in hands

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ASX 50 index is where investors will find many of the highest quality companies that the Australian share market has to offer.

But which of these companies could be good options for investors right now? Let's take a look at two ASX 50 shares that analysts rate very highly:

CSL Limited (ASX: CSL)

The first ASX 50 share that we are going to look at is CSL.

It is one of the world's leading biotechnology companies, comprising the CSL Behring, CSL Vifor, and Seqirus businesses.

Over many decades, CSL has spent tens of billions on research and development (R&D) activities and acquisitions. This has led to the company owning a portfolio filled to the brim with high quality therapies and vaccines.

But management is never one to rest on its laurels. The company continues to invests 10%-11% of its sales revenue back into R&D each year. This means that CSL has a large number of potentially lucrative and life-saving therapies under development that will support its future growth.

The team at Citi has been bullish on CSL for some time and this remains the case today. Particularly given how recent industry commentary supports its view that immunoglobulin demand will grow strongly in the coming years. It said:

We attended Takeda's virtual Plasma-Derived Therapies (PDT) investor event. Takeda is expecting mid-to-high single digit volume growth for Immunoglobulin (Ig) over the medium-term despite the competition from FcRns – this is in-line with CSL's expectations and our forecasts.

Citi has a buy rating and $325.00 price target on its shares.

Telstra Corporation Ltd (ASX: TLS)

Another ASX 50 share that is highly rated by analysts is Telstra. It is of course Australia's largest telecommunications company.

Telstra went through a difficult period in the 2010s following the launch of the NBN. Pleasingly, that is all behind the company now and growth is back on the agenda thanks to the success of its T22 strategy and the launch of its successor – T25.

Commenting on the strategy, its CEO at the time, Andy Penn, said: "If T22 was a strategy of necessity, T25 is a strategy for growth."

Goldman Sachs appears to have confidence in the strategy based on its earnings growth forecasts. In addition, the broker highlights that this growth is low risk, which makes it even more appealing for investors. It said:

We believe the low risk earnings (and dividend) growth that Telstra is delivering across FY22-25, underpinned through its mobile business, is attractive. We also believe that Telstra has a meaningful medium term opportunity to crystallise value through commencing the process to monetize its InfraCo Fixed assets – which we estimate could be worth between A$22-33bn.

Goldman currently has a buy rating and $4.65 price target on Telstra's shares.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Goldman Sachs Group. The Motley Fool Australia has positions in and has recommended Telstra Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Blue Chip Shares

The best ASX shares to buy and forget for 10+ years

Want to make long term investments? Here are three picks that brokers rate as buys.

Read more »

An ASX investor in a business shirt and tie looks at his computer screen and scratches his head with one hand wondering if he should buy ASX shares yet
Blue Chip Shares

This popular ASX 200 blue-chip share has literally gone nowhere in 17 years

Even blue-chip shares can fall short.

Read more »

Two smiling work colleagues discuss an investment or business plan at their office.
Blue Chip Shares

3 no-brainer ASX shares to buy now with $5,000

Brokers think these shares could be among the best to buy right now.

Read more »

Broker checking out the share price oh his smartphone and laptop.
Blue Chip Shares

2 ASX blue-chip shares offering big dividend yields

These businesses are predicted to pay significant passive income to shareholders.

Read more »

Smiling couple sitting on a couch with laptops fist pump each other.
Blue Chip Shares

2 dirt cheap ASX 200 blue chip shares to buy now with $10,000

Analysts think these cheap shares could be top buys.

Read more »

Young female investor smiling and speaking on mobile phone while sitting in front of laptop
Blue Chip Shares

Down 28% and 23%! Should I buy either of these 2 iconic ASX 200 shares?

These ASX blue-chips are trading at much cheaper prices. Are they buys to me?

Read more »

Multiracial happy young people stacking hands outside - University students hugging in college campus - Youth community concept with guys and girls standing together supporting each other.
Blue Chip Shares

5 ASX 200 blue chip shares to buy in FY26 with $5,000

Analysts think these shares could be top picks for the new financial year.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Blue Chip Shares

2 ASX stocks to hold for steady gains

Analysts think these stocks could deliver the goods for investors.

Read more »